Objective-Diabetic macular edema is a major cause of visual impairment. It is caused by blood-retinal barrier breakdown that leads to vascular hyperpermeability. Current therapeutic approaches consist of retinal photocoagulation or targeting VEGF (vascular endothelial growth factor) to limit vascular leakage. However, long-term intravitreal use of anti-VEGFs is associated with potential safety issues, and the identification of alternative regulators of vascular permeability may provide safer therapeutic options. The vascular specific BMP (bone morphogenetic protein) receptor ALK1 (activin-like kinase receptor type I) and its circulating ligand BMP9 have been shown to be potent vascular quiescence factors, but their role in the context of microvascular permeability associated with hyperglycemia has not been evaluated. Approach and Results-We investigated Alk1 signaling in hyperglycemic endothelial cells and assessed whether BMP9/ Alk1 signaling could modulate vascular permeability. We show that high glucose concentrations impair Alk1 signaling, both in cultured endothelial cells and in a streptozotocin model of mouse diabetes mellitus. We observed that Alk1 signaling participates in the maintenance of vascular barrier function, as Alk1 haploinsufficiency worsens the vascular leakage observed in diabetic mice. Conversely, sustained delivery of BMP9 by adenoviral vectors significantly decreased the loss of retinal barrier function in diabetic mice. Mechanistically, we demonstrate that Alk1 signaling prevents VEGF-induced phosphorylation of VE-cadherin and induces the expression of occludin, thus strengthening vascular barrier functions. Conclusions-From these data, we suggest that by preventing retinal vascular permeability, BMP9 could serve as a novel therapeutic agent for diabetic macular edema. Visual Overview-An online visual overview is available for this article.
D
iabetic patients frequently experience ischemic vascular disease or wound healing defects. It has been established that chronic hyperglycemia associated with diabetes mellitus causes endothelial cell (EC) dysfunction, glycosylation of extracellular matrix proteins, as well as vascular denervation. 1, 2 These adverse effects ultimately impair vascular function and significantly increase the risks of complications, such as renal failure, amputations, strokes, cardiopathies, and blindness. 3, 4 A frequent microvascular complication induced by diabetes mellitus is retinopathy, of which diabetic macular edema (DME) is a major consequence 5 and is the leading cause of blindness in the diabetic population. 6 It has been reported that 27% of type 1 diabetic patients go on to develop macular edema within 9 years after the onset of diabetes mellitus, whereas in type 2 diabetic patients, the prevalence ranges from 3% within 5 years of diagnosis to 28% after 20 years. 7 DME is a complex disease of multifactorial origin and is the consequence of destabilization of the blood-retinal barrier. 8 Blood-retinal barrier breakdown is typically caused by pericyte and endothelial cell loss and changes in vascular tight junctions, leading to vascular hyperpermeability. 7, 9 The disruption of the blood-retinal barrier leads to the accumulation of fluid into the retina, resulting in tissue damage and, eventually, to vision loss. 10 The pathogenesis of DME is thought to occur as a consequence of chronic hyperglycemia, along with the accumulation of free radicals, AGE (advanced glycation end product) proteins, and the subsequent induction of VEGF (vascular endothelial growth factor), 11 leading to increased vascular permeability. 7, 10 Mechanistically, increased vascular permeability occurs as a consequence of disrupted cell-cell junctions in the endothelium and loss of junctional proteins, such as occludin. [12] [13] [14] [15] Furthermore, increased VEGF signaling 16 can promote the activation of Src through the phosphorylation of VEGFR (VEGF receptor) 2, which leads to the phosphorylation and internalization of VE-cadherin and the loss of vascular adherens junctions. 13, [17] [18] [19] [20] Clinical trials and recent approval of anti-VEGFs for the treatment of diabetic retinopathy and DME have shown the benefits of VEGF inhibition for the prevention of vascular leakage and have demonstrated beneficial effects on visual acuity and retinal thickness. [21] [22] [23] [24] [25] However, despite encouraging results, intravitreal injection of anti-VEGF agents may be associated with systemic adverse events and devastating ocular complications. 26 Thus, there is a need to identify alternative signaling pathways to prevent vascular leakage in DME.
Among the causative factors involved in the progression of cardiovascular damage in diabetes mellitus is pericyte loss, increased capillary permeability, new vessel formation, endothelial cell death, and capillary occlusion. 27 These features of the pathological diabetic endothelium are characteristics of immature, poorly remodeled blood vessels. In this regard, the endothelial-specific receptor Alk1 (activin-like kinase receptor type I) has been shown to be a critical inducer of blood vessel remodeling and maturation during vascular development. [28] [29] [30] Alk1 is a TGF-β/BMP (bone morphogenetic protein) receptor expressed in endothelial cells. 31 After ligand binding, the activated receptor propagates the signal by phosphorylating members of the Smad (suppressor of mothers against decapentaplegic) family of transcription factors. 31, 32 Non-Smad signaling pathways have also been described for BMPs. [33] [34] [35] Recently published studies suggest that BMP9, which is produced by the liver and circulates in the bloodstream, 36 binds with high affinity to Alk1 in association with type II BMP receptors, including BMPR2 (BMP receptor 2) and ActRIIB (activin receptor 2B). [37] [38] [39] [40] [41] Mice lacking Alk1 die early during embryonic development (E11) because of a severe lack of vascular remodeling. 30 The vessels in these mice are characterized by enlarged lumen, inadequate pericyte coverage, and increased proliferation, which leads to blood vessel rupture and hemorrhages. [42] [43] [44] [45] In addition, we have previously shown that triggering Alk1 signaling in endothelial cells using its ligand BMP9 prevents VEGF-induced signaling and promotes mature, stable vessels. 35 Hence, the phenotype associated with Alk1 deficiency is reminiscent of the vascular pathology observed in diabetic retinopathy. We, therefore, hypothesize that promoting Alk1 signaling in endothelial cells subjected to chronic hyperglycemic stress may prevent vascular damage and loss of junctional integrity leading to permeability.
Here, we examined the protective role of BMP9 on hyperglycemia-induced vascular permeability in streptozotocin (STZ)-treated diabetic mice and human endothelial cells. The effect of BMP9 in VEGF-independent and dependent microvascular permeability through key subcellular mechanisms and adherens and tight junction integrity in endothelial cells were evaluated. We demonstrated that BMP9/Alk1 signaling is impaired in endothelial cells exposed to hyperglycemic conditions, which can contribute to increased vascular permeability. Exogenous BMP9 was able to prevent vascular permeability in both endothelial cells subjected to hyperglycemia and STZ-treated diabetic mice. Mechanistically, we showed that BMP9/Alk1 signaling induced the expression of occludin and prevented VEGF-induced VE-cadherin phosphorylation and stabilized adherens junctions.
Materials and Methods
The authors declare that all supporting data are available within the article and its online-only Data Supplement.
Cell Culture
Human umbilical endothelial cells (HUVECs) were obtained from PromoCell and human retinal microvascular endothelial cells (HRMECs) were obtained from Cell Systems and cultured in ECGM-2 (endothelial cell growth medium 2; Lonza) and kept at 37°C and 5% CO2. For most experiments, cells were seeded in 6-well plates or 8 wells Millicell EZ Slide (Millipore) and grown to confluence before starvation overnight in endothelial basal media (EBM-2) minimal media (Lonza) supplemented with 0.5% fetal bovine serum (FBS) while exposed to D-glucose (5, 11, or 25 mmol/L) with or without BMP9 treatment for 18 hours. Because EBM-2 already contains 5 mmol/L of D-glucose, differential addition of glucose was added to media to obtain final concentrations.
Animals
C57BL/6J mice (Jackson Laboratories) were maintained in the animal research facility in Maisonneuve-Rosemont Hospital. All protocols were approved by the Animal Research Ethics Committee of the research center. Tamoxifen-inducible Cdh5-CreErt2 and acvrl1 floxed mice were kindly provided by Ralf Adams and S. Paul Oh, respectively. Cdh5-CreErt2 mice were crossed with acvrl1 floxed mice, and gene deletion was induced by injection of 100 mg/kg tamoxifen dissolved in corn oil for 5 consecutive days to produce Alk1ΔEC mice. Cdh5-CreErt2 mice lacking the acvrl1 floxed allele injected with tamoxifen were used as control. To avoid variability, only males were used for all experiments as they are more susceptible to STZ-induced diabetes mellitus.
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Antibodies and Reagents
The following primary antibodies were used: ALK1 (human AF370 or mouse AF770; 0.4 µg/mL) and Eng (AF1320; 0.2 µg/mL) were obtained from R&D Systems. pSmad1, 5, 9 (cs9511; 10 µmol/L), Smad1 (cs6944; 10 µmol/L), pVEGFR2-Y951 (cs4991; 10 µmol/L), , 0.25 µg/mL; immunohistochemistry, 0.8 µg/mL; Thermo Scientific) and VE-cadherin (sc9989; 0.2 µg/mL) were used for WB, whereas anti-VE-cadherin (sc6458; 1 µg/mL) was used for immunohistochemistry (Santa Cruz). Anti-β-actin (sc47778; 0.1 µg/mL) and β-catenin (sc7963; 0.2 µg/mL) were acquired from Santa Cruz. Claudin-5 (352588; 0.5 µg/mL) was purchased from Invitrogen. Recombinant human proteins rhBMP9 (recombinant human BMP9) and rhVEGF-165 were obtained from R&D systems. Validated, predesigned siRNAs against OCCLUDIN (AM16708; Ambion, Inc), ACVRL1 (s102659972), or scrambled control (Qiagen) were used for permeability and signaling assays.
Nonstandard Abbreviations and Acronyms
STZ-Induced Diabetes Mellitus
Six-to 8-week old C57BL/6J, Cdh5-CreErt2, or Alk1ΔEC male mice were individually marked, weighed, and their baseline blood glucose levels determined before STZ injection. Mice received daily intraperitoneal injections of 45 mg/kg body weight STZ (Sigma-S0130) dissolved in sterile sodium citrate dehydrate buffer, pH 4.5, for 5 consecutive days. 47, 48 For nondiabetic controls, mice received citrate buffer injections. Tail blood glucose was monitored (AlphaTrak 2) every week for ≤8 weeks after the final STZ injection. Mice were considered diabetic if their nonfasted blood glucose levels reached 17 mmol/L (300 mg/dL).
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Adenovirally Delivered BMP9 System
Adenoviral constructs were produced and purified as described previously. 35 Mice groups with stable hyperglycemia were randomly assigned to receive intraperitoneal injections of 5×10 8 pfu of adenovirally delivered BMP9 system or empty vehicle adenovirus (control) once every 4 weeks.
Flow Cytometry Analysis of Cell Surface Expression/Receptor Internalization
HUVECs cultured in the presence of 5, 11, or 25 mmol/L D-glucose for 18 hours were stimulated with or without 5 ng/mL BMP9 for 30 minutes. Receptor internalization was halted by shifting the cells to ice followed by 2 washes in ice-cold PBS. Noninternalized ligand was stripped from the cell surface using freshly prepared, ice-cold acid stripping buffer (DMEM/0.2% BSA, pH 3.5 adjusted with HCl), followed by PBS washes. Cells were then incubated in the presence of ALK1 antibody (AF370; R&D systems; 1 µg/mL) or goat isotype control for 1 hour in FACS (fluorescence-activated cell sorting) buffer (PBS/2% FBS). After washing the cells 3× with ice-cold PBS, the cells were incubated in cold FACS buffer containing 1 μg/mL of antigoat Alexa488-conjugated secondary antibody for 1 hour on ice. After washes, cells were analyzed using a Fortessa (BD Biosciences) and analyzed with FlowJo (TreeStar, Ashland, OR). The mean fluorescence intensity of the cells for each data set was compared with negative control plates stained with an isotype antibody and the secondary antibody.
In Vivo Miles Assay for Vessel Permeability
Mice were injected intravenously with Evans blue dye (Sigma; 45 µg/g of mice weight) and 2 hours later were perfused with 9 mL of PBS. Immediately after, eyes were enucleated and fixed in 4% paraformaldehyde, and retinas were microsurgically removed and placed in formamide for 24 hours at 65°C for Evans blue extraction. Retinas were then dried and weighed on cotton wool paper. Absorbance maximum at 620 nm was read with a spectrophotometer (TECAN 1000). A background minimum absorbance at 740 nm was subtracted. The concentration of dye in the extracts was calculated from a standard curve of Evans blue in formamide. Retinal vascular permeability was normalized taking into consideration circulating Evans blue plasma concentration, retinal dry weight, and time of Evans blue circulation and calculated using a previously described equation. 48, 49 To evaluate the functional mechanism by which BMP9 affects vascular leakage, a modified Miles assay on skin was performed. 50 Briefly, shaved mice injected 3 days prior with adenoviral particles were injected intravenously with 150 µL of Evans blue in PBS (10 mg/mL) for 30 minutes, followed by subcutaneous injections of 50 µL VEGF (1 ng/µL) or PBS. 51 After 45 minutes, mice were euthanized, and equal dimension of skin regions sites were excised and placed in formamide for 48 hours at 65°C for Evans blue extraction, followed by absorbance measurements with a microplate reader at 620 nm.
In Vitro EC Monolayer Permeability Assay
In vitro Evans blue permeation assays were performed as described previously. 52 HUVECs were seeded (1.5 mL; 2×10 5 cells) on the upper chamber of a fibronectin-coated transwell insert (0.4 µm pore size; Costar 6 Transwell permeable support [Corning]), and 3 mL of EGM-2 media was placed in the lower chamber. Cells were grown until full confluency was reached and were exposed to hyperglycemia or normoglycemia and treated with BMP9 as described above. After 18 hours, Evans blue bound to albumin (2 mg of Evans blue/100 mL of EBM-2 supplemented with 0.5% FBS-0.1% BSA) was added for 90 minutes in the upper chamber. The same media without Evans blue was added to the lower chamber. To determine Evans blue/albumin extravasation across the EC layer, 1-mL samples were then removed from each side of chamber, vortexed, and the Evans blue concentration in the upper and lower chambers was measured at 620 nm for quantitative analysis, which was determined by calculating the Evans blue ratio in the lower/upper chambers. In some experiments, HUVECs were transfected with control or OCCLUDIN siRNA (2.5 pmol) 24 hours before seeding.
In Vitro Electric Cell-Substrate Impedance Sensing System Permeability Assay
Endothelial barrier function analysis was achieved using electric cellsubstrate impedance sensing system (ECIS Zθ; Applied Biophysics). HUVECs and HRMECs were seeded on collagen-coated electric cell-substrate impedance sensing system arrays each holding 8 wells with 10 electrodes per well (8W10E PET; Applied Biophysics). Electrodes were calibrated, and baseline monitoring was measured for 1 hour before cell inoculation. Initial seeding density was ≈50 000 cells per cm 2 for at least 24 hours at 37°C in complete ECGM-2. The impedance of the cell culture was monitored with multiple frequency/ time mode for the real-time assessment of barrier function and cell monolayer confluency was estimated before rhBMP9 treatment (10 ng/mL) for 18 hours in minimal media containing 0.5% FBS. For the assessment of cell permeability after treatment, D-glucose was added for final concentrations of 11 or 25 mmol/L and monitored in real time for 6 hours. To assess the disruption of the EC barrier through paracellular pathway on administration of D-glucose, a frequency of 4000 hz was assessed for further analysis.
Immunohistochemistry
HUVECs were grown on 8-well Millicell EZ slides. After treatment, cells were permeabilized for 3 to 5 minutes with pre-extraction buffer (0.1% Triton, 100 mmol/L KCl, 3 mmol/L MgCl2, 1 mmol/L CaCl2, 200 mmol/L sucrose, and 10 mmol/L Hepes in PBS) and fixed with ice-cold methanol for 5 minutes. In between washes, cells were incubated with primary antibodies in PBS-3% BSA O/N at 40°C. Cells were then incubated with secondary antibodies for 2 hours at room temperature in blocking medium. Slides were then mounted with fluoromount containing DAPI (4',6-diamidino-2-phenylindole; Sigma) and visualized by confocal microscopy. Z stacks were acquired and reconstructed into a 3-dimensional cell monolayer with Imaris software. For in vivo retinal immunohistochemistry permeability visualization, lens was removed on extraction, and ocular globes were snap frozen in optimal cutting temperature compound molds using liquid nitrogen. Cross sections of eyes were visualized after incubation with Alexa 488-labeled IsoB4 (isolectin B4), and Evans blue/albumin extravasation was visualized by confocal microscopy. 49 
Statistical Analysis
All statistics were performed with the Graphpad Prism 5.01 software. In experiments evaluating differences between 2 experimental groups, significance was assessed using Student t test. ANOVA was used to evaluate statistical significance between ≥3 groups. If the P value was <0.05, Tukey post hoc multiple comparison tests were performed to compare differences between pairs of means. For colocalization experiments, Pearson correlation coefficient (calculated using the COLOC toolkit) was used. 53 All group data are shown as mean±SEM, and a P value <0.05 was considered statistically significant.
Results
Hyperglycemia Inhibits BMP9/ALK1/ Smad1, 5, 9 Signaling in Endothelial Cells
To investigate Alk1/BMP9 signaling in the vascular endothelium during hyperglycemic insult, we first exposed HUVECs for 18 hours to increasing concentrations of D-glucose (ie, 5, 11, and 25 mmol/L; Figure 1A ) or its nonmetabolizable enantiomer, L-glucose ( Figure IA in the online-only Data Supplement), followed by stimulation with 1 ng/mL BMP9 for ≤60 minutes. Immunoblotting showed that BMP9 induced rapid phosphorylation of Smad1, 5, 9 at 5 mmol/L D-glucose, but this was inhibited when cells were exposed to 11 mmol/L D-glucose ( Figure 1A ). This inhibition was not observed in the presence of L-glucose, which is not metabolized by mammalian cells 54 ( Figure IA in the online-only Data Supplement). A 2-hour pretreatment with D-glucose was sufficient to inhibit BMP9/ALK1 signaling, but the greatest inhibition was observed after 18 hours (Figure IB in the online-only Data Supplement). A dose response of BMP9 under different concentrations of glucose also revealed that hyperglycemia inhibited BMP9 signaling at concentrations of ≤1 ng/ mL, whereas no significant inhibition of ALK1 signaling was observed at higher concentrations of BMP9 ( Figure IC in the online-only Data Supplement). Considering that endothelium of microvascular and macrovascular origins can respond differently to hyperglycemia, we also evaluated the effects of high glucose concentrations in human retinal microvascular endothelial cells (HRMECs) . Similarly to what we observed in HUVECs, a significant inhibition of BMP9/Smad1, 5, 9 signaling was observed in HRMECs at 11 mmol/L D-glucose ( Figure ID in the online-only Data Supplement). These changes in BMP9/Smad1, 5, 9 signaling in hyperglycemic ECs were associated with significantly decreased levels of the ALK1 receptor after 18 hours ( Figure 1B) . A time course also revealed that ALK1 levels started to decrease after 6-hour exposition to 11 mmol/L D-glucose and maintained low expression for ≤72 hours ( Figure IE in the online-only Data Supplement). Whereas ALK1 protein levels were decreased, significant changes in the expression of endoglin or type II BMP receptors BMPR2 and ActRIIB were, however, not observed ( Figure 1B) .
Because hyperglycemia has recently been shown to alter the localization and signaling of endothelial receptors, including VEGFR2, 55 we evaluated the consequences of high glucose concentrations on Alk1 cell surface localization and internalization after BMP9 stimulation. Flow cytometry analysis of unpermeabilized HUVECs showed a significant reduction in cell surface expression of ALK1 in the presence of 11 and 25 mmol/L D-glucose ( Figure 1C) . Treatment of HUVECs with BMP9 resulted in decreased cell surface localization of ALK1 after 30 minutes at 5 mmol/L glucose, consistent with receptor internalization ( Figure 1D ). However, ALK1 internalization after BMP9 stimulation was significantly impaired in HUVECs cultured in the presence of 11 or 25 mmol/L glucose ( Figure 1D ). Using immunofluorescent staining, we also observed that ALK1 undergoes rapid internalization in HUVECs after BMP9 treatment in normoglycemic conditions, in line with our flow cytometry data and previously published results ( Figure IF in the online-only Data Supplement). 56 However, the intensity of ALK1 immunostaining and the number of internalization vesicles after BMP9 stimulation were significantly reduced under hyperglycemic conditions (11 mmol/L; Figure IF in the online-only Data Supplement). Together, these data suggest that high glucose levels reduce Alk1 cell surface expression, while preventing receptor internalization after ligand stimulation, which may account for decreased BMP9-induced Smad1, 5, 9 phosphorylation observed in hyperglycemic ECs.
We next evaluated whether we could detect changes in BMP9/Alk1/Smad1, 5, 9 signaling in the endothelium of hyperglycemic mice. Diabetes mellitus was induced in C57BL/6J mice using STZ, as described previously. [47] [48] [49] Mice with blood glucose consistently >17 mmol/L were considered diabetic. 57 Eight weeks after the onset of hyperglycemia, analysis of circulating BMP9 levels by ELISA showed no significant differences between normoglycemic and diabetic groups ( Figure IG in the online-only Data Supplement). By contrast, we observed a significant reduction in the levels of Alk1 in endothelial-rich pulmonary tissue, which was associated with reduced Smad1, 5, 9 phosphorylation ( Figure 1E ). Immunofluorescent staining of retinas harvested from diabetic mice 8 weeks after STZ injections also revealed a substantial decreased in Alk1 staining in retinal blood vessels ( Figure 1F ). experiments. E, Six-to 8-wk-old C57/BL6 mice were injected intraperitoneally with streptozotocin (STZ). Eight weeks after onset of diabetes mellitus, pulmonary tissue was harvested, and homogenates were analyzed with specific antibodies by immunoblotting. Blots were quantified by densitometry (bottom). n=5 control mice, n=4 diabetic (DB) mice. F, Immunofluorescence on retinal cryosections revealed that Alk1 protein (green) shows robust vascular expression in control retinas (top) but is weakly expressed in blood vessels at 8 wk after STZ injection (bottom), as confirmed by colocalization with the vascular marker IsoB4. Representative images of 3 independent mice (scale bar=40 μm). Differences between means were analyzed using unpaired t test. NS indicates nonsignificant. *P<0.05, **P<0.01, ***P<0.001.
Together, these data suggest that hyperglycemia impairs Alk1 expression and signaling in endothelial cells.
Alk1 Haploinsufficiency Exacerbates Retinal Vascular Permeability in Diabetic Mice
Alk1 plays an important role in the maintenance of vascular integrity, and impaired BMP9/Alk1 signaling results in increased vascular permeability. 58 Because our data show a significant reduction in BMP9/Alk1/Smad1, 5, 9 signaling in the hyperglycemic endothelium, we postulated that Alk1 signaling may prevent vascular permeability in the retina and that its inhibition in diabetic conditions could exacerbate hyperglycemia-induced vascular leakage (Figure 2 ). We first evaluated whether specific loss of endothelial Alk1 was implicated in retinal vascular permeability under physiological conditions using mice with conditional deletion of acvrl1 in the endothelium (Alk1ΔEC). To detect vascular permeability, retinal Evans blue/albumin permeation was assessed as described previously. 48, 49 Deletion of endothelial Alk1 protein in Alk1ΔEC mice after tamoxifen injections was confirmed by immunoblotting of lung tissue and immunofluorescent staining of retinas ( Figure IIA and IIB in the onlineonly Data Supplement). Although Evans blue permeability in nondiabetic Alk1ΔEC heterozygoteous mice was not significantly different from control animals 8 weeks after tamoxifen injections (Figure 2A ), homozygous deletion of endothelial Alk1 in nondiabetic mice showed significantly higher retinal vascular albumin extravasation compared with control mice after 7 days ( Figure 2B) . Permeability experiments were performed after 7 days of deletion in Alk1ΔEC homozygous mice, as opposed to 8 weeks in heterozygous animals, because Alk1ΔEC homozygous mice display high lethality starting 10 days after tamoxifen injections. Although homozygote Alk1ΔEC mice display enhanced retinal vascular permeability, no morphological changes, such as arteriovenous malformations or dilation of the retinal vasculature, were observed in adult mice 7 days after tamoxifen injection ( Figure IIB in the online-only Data Supplement).
In light of our data suggesting that Alk1 levels are decreased in hyperglycemic mice, we evaluated whether Alk1 haploinsufficient mice would be more susceptible to hyperglycemia-induced vascular leakage. To address this, control and heterozygous Alk1ΔEC mice were injected with STZ to induce diabetes mellitus, and 8 weeks after induction of diabetes mellitus, Evans blue permeation was evaluated in retinas ( Figure 2C) . 48, 49 Histological assessment of the retinal vasculature revealed no significant difference in retinal capillaries between control and heterozygous Alk1ΔEC diabetic mice ( Figure IIC in the online-only Data Supplement). However, as reported, 48, [59] [60] [61] [62] we observed an increase in Evans blue permeability in diabetic control mice compared with nondiabetic mice (Figure 2D ). Furthermore, although we had previously observed that nondiabetic heterozygous Alk1ΔEC mice did not show any differences in vascular permeability (Figure 2A ), they displayed a significant increase in retinal vascular permeability compared with control mice in diabetic Blood glucose levels were monitored twice per week. When peak average glycaemia was reached 2 wk after STZ injection, Ad-control or adenovirally delivered BMP9 system (Ad-BMP9) were injected intraperitoneally. Control (CTL; n=7 mice), Ad-CTL (n=8 mice), (Continued ) conditions ( Figure 2D ). These data suggest that Alk1 signaling contributes to the maintenance of vascular integrity and that reduced Alk1 signaling can predispose to chronic hyperglycemia-induced vascular permeability.
BMP9 Prevents Vascular Barrier Permeability in Diabetic Retinas and Hyperglycemic Endothelial Monolayer
Because loss of Alk1 signaling exacerbates hyperglycemiainduced vascular permeability, we evaluated whether activation of Alk1 signaling could prevent vascular permeability induced by hyperglycemia. As our data show that BMP9 signaling is impaired in hyperglycemic endothelial cells because of reduced Alk1 expression, we used higher concentrations of BMP9 (10 ng/mL) to more readily activate Alk1 signaling ( Figure IC in the online-only Data Supplement). HUVEC monolayers plated in transwells were treated with or without rhBMP9 for 18 hours in normoglycemic (5 mmol/L) and hyperglycemic (11 and 25 mmol/L) conditions, and diffusion of Evans blue from the upper chamber to the lower chamber was measured after 90 minutes. Our results show that hyperglycemia induces a significant increase in endothelial permeability and that BMP9 pretreatment prevented EB-albumin permeability across the EC monolayer under hyperglycemic conditions (25 mmol/L; Figure 3A ). These data were also reproduced in retinal microvascular endothelial cells. HRMECs were subjected to high glucose and subjected to Evans blue permeability. Even though these ECs were less permeable than HUVECs when subjected to high glucose, BMP9 did reduce EB-albumin permeability at 25 mmol/L glucose ( Figure IIIA in the online-only Data Supplement).
Further evidence for the ability of BMP9 to preserve endothelial barrier function was obtained from real-time analysis of transendothelial electric resistance. 63 Treatment of an intact monolayer of HUVECs ( Figure 3B ) or HRMECs ( Figure  IIIB and IIIC in the online-only Data Supplement) with 25 mmol/L D-glucose reduced endothelial monolayer impedance and hence provoked a drop in barrier function in the first 6 hours after D-glucose treatment. However, both HUVECs and HRMECs pretreated with BMP9 for 18 hours showed a markedly reduced drop in endothelial monolayer impedance (measured from an interval between 0 and 6 hours post-glucose stimulation), confirming that BMP9 can help prevent hyperglycemia-induced permeability.
We then inquired whether overexpression of circulating BMP9 using adenoviral gene delivery could prevent retinal vascular leakage in diabetic mice. STZ-treated mice received intraperitoneal injections of adenoviral BMP9 for 8 weeks, which resulted in consistently elevated levels of circulating BMP9 (≈123 pg/mL after 8 weeks; Figure IIID in the online-only Data Supplement). No significant changes in mouse weight were observed throughout the length of the experiment ( Figure IIIE in the online-only Data Supplement). Interestingly, measurements of glycaemia after adenoviral BMP9 injections showed a small but significant decrease in average blood glucose compared with baseline Ad-CTL levels ( Figure 3C ), which is consistent with a previous report showing that injections of rhBMP9 in mice reduce glycemia through the inhibition of gluconeogenesis. 64 Sustained overexpression of BMP9 for 8 weeks resulted in a significant decrease of vascular retinal Evans blue permeability in diabetic mice, compared with diabetic mice treated with control adenoviruses, with levels comparable with nondiabetic baseline ( Figure 3D ). Visual appreciation of Evans blue permeability on retinal cross sections showed Evans blue extravasation localization in the inner retinal blood barrier, which was not observed in BMP9-overexpressing diabetic mice ( Figure 3E ). It is noteworthy that no changes in perivascular cell coverage (SMA-positive smooth muscle cells or desmin-positive pericytes) were observed in these retinas during the experimental time frame ( Figure IIIF and IIIG in the online-only Data Supplement).
BMP9 Limits Vascular Permeability via Inhibition of VEGF/VEGFR2 Signaling
VEGF signaling plays a pivotal role in vascular permeability leading to the development of DME. 12, 22, 25, 65 Therefore, we investigated the underlying mechanisms behind BMP9-mediated inhibition of permeability and whether it can prevent vascular leakage through the modulation of VEGF-induced permeability. To address this, we first assessed whether BMP9 overexpression could suppress VEGF-induced permeability in a Miles assay. Mice were injected with adenovirally delivered BMP9 system or Ad-CTL, and 72 hours later, after confirmation of BMP9 overexpression, we measured vascular permeability in response to VEGF by injecting recombinant VEGF subcutaneously and measuring Evans blue leakage. Our data demonstrate, as established previously, that VEGF significantly increases albumin-bound Evans blue permeability by ≈2.5-fold relative to PBS injections [66] [67] [68] [69] ( Figure 4A and 4B). However, BMP9-overexpressing mice displayed significantly decreased VEGF-induced EB-albumin permeability. We could show that the effect of BMP9 on VEGF-induced permeability was dependent on vascular Alk1 expression in this assay because overexpression of adenovirally delivered BMP9 system in Alk1ΔEC homozygote mice did not prevent VEGFinduced permeability ( Figure 4A ). VEGF loosens cell junctions by activating a molecular cascade, which results in the phosphorylation and internalization of VE-cadherin. 20 We, therefore, evaluated whether BMP9 affects the VEGF signaling cascade leading to the loss of adherens cell junctions. VEGFR2 is a key receptor in VEGF-mediated downstream signal transduction. After VEGF stimulation, VEGFR2 is phosphorylated at position Tyr951 in the intracellular domain, which leads to Src phosphorylation, resulting in the phosphorylation and internalization of VE-cadherin. 70, 71 To evaluate the effects of BMP9 and hyperglycemia on VEGF signaling, HUVECs were treated with D-glucose (5, 11, or 25 mmol/L) in the presence or absence of BMP9 (10 ng/mL) for 18 hours before VEGF stimulation. Protein extracts from stimulated cells were harvested and processed for immunoblotting. We found that regardless of glucose levels, VEGFR2 Tyr951 phosphorylation was inhibited when HUVECs were pretreated for 18 hours with rhBMP9 before VEGF stimulation ( Figure 4C ). Because Src activation plays an essential role in VEGF-mediated permeability, 67 we investigated whether EC pretreatment with BMP9 in the same conditions could prevent Src phosphorylation in normoglycemic and hyperglycemic conditions. Our data show that Src phosphorylation is increased in ECs exposed to VEGF and that BMP9 prevents Src phosphorylation in both hyperglycemic and normoglycemic conditions ( Figure 4C ). Downstream of Src phosphorylation, phosphorylation of VE-cadherin has been shown to regulate vascular permeability because phosphorylation of VE-cadherin at Tyr685 72 controls the opening of endothelial cell junctions. 73, 74 Hence, we analyzed whether BMP9 signal transduction alters the phosphorylation status of VE-cadherin in hyperglycemic conditions. On VEGF stimulation, phosphorylation of VE-cadherin was triggered. This increase in VEGF-dependent VE-cadherin phosphorylation was markedly increased at high glucose concentrations (25 mmol/L). However, prestimulation of HUVECs with BMP9 abrogated VEGF-induced phosphorylation of VE-cadherin, both in normoglycemic and hyperglycemic conditions ( Figure 4C ). Interestingly, although high glucose concentrations did not alter levels of β-catenin, BMP9 stimulation resulted in higher levels of β-catenin. High levels of β-catenin in BMP9-stimulated cells may contribute to decreased VEGFR2 phosphorylation because β-catenin has previously been demonstrated to inhibit VEGFR2 phosphorylation. 75 Finally, VEGF-induced phosphorylation of eNOS and subsequent modulation of NO levels have also been shown to be mediators of vascular permeability in diabetes mellitus [76] [77] [78] and are thought to be key factors in the occurrence and development of DME, 12, 79, 80 decreasing the expression of cell junction proteins and leading to blood-retinal barrier breakdown. Our data show an increase in eNOS phosphorylation in ECs stimulated with 11 mmol/L D-glucose on VEGF stimulation, which was reduced by rhBMP9 pretreatment ( Figure 4C ). Using HRMECs, we also observed that BMP9 prevented VEGF-induced phosphorylation of VEGFR2, Src, VE-cadherin, and eNOS in both normoglycemic and hyperglycemic microvascular endothelial cells ( Figure IVA in the online-only Data Supplement). Together, these data show that BMP9 can prevent key VEGF signaling events leading to the loss of endothelial adherens junctions.
Conversely, we observed that ALK1 loss-of-function led to increased VEGF-induced phosphorylation of the same key pathways involved in vascular permeability. HUVECs transfected with ACVRL1 siRNA displayed increased phosphorylation of VEGFR2 Tyr951 after VEGF stimulation, which exacerbated downstream Src and VE-cadherin phosphorylation ( Figure 4D ). HRMECs transfected with ACVRL1 siRNA also displayed exacerbated phosphorylation of VEGFR2, Src, VE-cadherin, and eNOS ( Figure IVB in the online-only Data Supplement). These observations were also confirmed in vivo in lung tissue extracted from homozygous Alk1ΔEC mice ( Figure 4D) . Together, our data show that BMP9 could prevent vascular permeability, in part, by mitigating VEGF signaling in endothelial cells.
BMP9/Alk1 Stabilizes Occludin Membrane Localization in Human ECs
Chronic hyperglycemia leads to destabilization of adherens and tight junctions in the endothelium.
14 For example, reduced vascular expression of the tight junction protein occludin has been reported in diabetes mellitus.
14 Furthermore, it is proposed that VEGF signaling, through phosphorylation of Src, leads to the internalization of VE-cadherin and the subsequent disruption of adherens junctions. 15, 20 We, therefore, assessed whether BMP9 could modulate the expression of OCCLUDIN and VE-cadherin in ECs. Analysis by quantitative polymerase chain reaction of HUVECs treated with BMP9 for 3 hours showed that BMP9 significantly induced the expression of OCCLUDIN but had no effect on VE-cadherin mRNA levels ( Figure 5A ). However, WB analysis revealed that VE-cadherin protein levels are reduced in HUVEC exposed to hyperglycemia at 11 mmol/L and 25 mmol/L of D-glucose but that BMP9 pretreatment stabilizes VE-cadherin levels in hyperglycemic conditions ( Figures 4C and 5B) , suggesting that high glucose lead to decreased VE-cadherin levels independent of gene transcription. We also evaluated the expression levels of claudin-5-an integral membrane protein and component of tight junctions-in response to hyperglycemia and BMP9 treatment but did not observe any significant changes ( Figure 4C ). However, we observed that the levels of the tight junction protein occludin, whose expression has been shown to correlate with an improved retinal vascular barrier function, [81] [82] [83] were significantly increased by BMP9 in normoglycemic and hyperglycemic conditions ( Figure 5B ).
Although BMP9 maintained high levels of occludin, its expression was decreased in HUVECs transduced with ACVRL1 siRNA and in Alk1ΔEC mice ( Figure 5C ). Confocal 3-dimensional rendering and quantification of HUVEC monolayers exposed to BMP9 or hyperglycemia show consistently that hyperglycemia reduces junctional colocalization of VE-cadherin and occludin at the junctional interface Figure 4 Continued. antibodies directed against VEGF pathway signaling or permeability proteins. Densitometry quantification of a representative experiment is shown (bottom; n=3 experiments). D, HUVECs transfected with control or ACVRL1 (activin-A receptor type II-like kinase 1) siRNA (25 pmol per well; left) were stimulated with or without VEGF (20 ng/mL; n=3 experiments), and lung tissue extracted from homozygote Alk1ΔEC mice (right) was processed for immunoblotting with antibodies of signaling molecules involved in vascular permeability. β-Actin antibodies were used to control for total protein levels or with total protein normalization. Bottom, Quantification of immunoblots performed on lung tissues (n=3 mice per group). Data±SEM are shown, and differences between means were analyzed using t test. *P<0.05, **P<0.01, ***P<0.001. Figure 5D ; Figure VA in the online-only Data Supplement). To evaluate the contribution of occludin to BMP9's antipermeability properties, HUVECs were transfected with control or OCCLUDIN siRNA ( Figure VC in the online-only Data Supplement) and treated with BMP9 in normoglycemic or hyperglycemic conditions. As shown previously, 84, 85 we observed increased Evans blue leakage in the presence of elevated glucose concentrations (11 mmol/L) and an inhibition in the presence of rhBMP9 ( Figure 5E ). As expected, cells transfected with OCCLUDIN siRNA displayed increased permeability compared with control cells. Furthermore, BMP9 did not significantly inhibit hyperglycemia-induced permeability in the absence of occludin ( Figure 5E ). Together, these data suggest that BMP9/Alk1 signaling can participate in the maintenance of cellular junctions through its induction of occludin expression under hyperglycemic conditions.
Discussion
Chronic uncontrolled hyperglycemia can lead to increased retinal capillary permeability, resulting in the leakage of fluid into the surrounding tissue, causing macular edema and loss of visual acuity. 25, 27, 86, 87 Although anti-VEGF therapies have shown significant promise in the treatment of proliferating vessels in proliferative diabetic retinopathies, patients with DME seem to be more resistant to these treatments, suggesting that other factors might contribute to the retinal vascular leakage. [88] [89] [90] Recent studies have indeed suggested that VEGFindependent mechanisms, such as carbonic anhydrase, 91 netrins, 92 erythropoietin, 93, 94 and semaphorin 3A, 49 also play a role in vascular permeability in DME. The data we present here suggest that the endothelial-specific receptor Alk1 participates in the maintenance of endothelial junctions via 2 distinct mechanisms: (1) by blocking VEGF-induced phosphorylation of Src and VE-cadherin and (2) in a VEGF-independent manner, by solidifying occludin junctions. Disruption of Alk1 under hyperglycemic conditions thus contributes to the loss of vascular integrity in DME ( Figure VI in the online-only Data Supplement).
Alk1 signaling is critical for the development of mature, functional vessels, as is made evident by the phenotype of Alk1-deficient mice, which die by midgestation and display severe vascular developmental defects, including fusion of major arteries and veins, impaired placental vascular development, and deficient perivascular cell coverage. 45, 95 Although many studies have helped uncover the mechanisms by which Alk1 contributes to vascular remodeling, 35, [96] [97] [98] [99] its roles in the maintenance of endothelial junctions and vascular permeability are still unclear. A study by Rudini et al 100 showed that Alk1 coimmunoprecipitates with VE-cadherin, suggesting that it could play a role in the maintenance of stable endothelial junctions. We show here that BMP9/Alk1 signaling prevents vascular leakage and that its loss leads to disrupted endothelial junctions and increased permeability. Our data suggest that this effect could originate at least, in part, by limiting VEGFR2 signaling, which results in reduced Src phosphorylation and internalization of VE-cadherin, and by promoting the expression of occludin, which is involved in the formation of tight junctions. Interestingly, a recent study by Ola et al 98 has shown that loss of Alk1 results in increased phosphorylation of VEGFR2 on tyrosine 1175, which may be a consequence of decreased VEGFR1 levels. Our data show that Alk1 also limits the phosphorylation of tyrosine 951 of VEGFR2, which is critical for the recruitment and phosphorylation of Src and the downstream phosphorylation of VE-cahderin. 70, 71 Alternatively, decreased VEGFR2 phosphorylation and downstream VEGF signaling in BMP9-treated ECs may be a consequence of elevated levels of β-catenin, which has previously been shown to restrict VEGFR2 phosphorylation, 75 although the mechanisms by which BMP9 affects β-catenin levels are unclear.
Alk1 also participates in vascular barrier functions by promoting the expression of occludin 101 -an important transmembrane protein involved in the maintenance of tight junctions. Studies have shown that tight junction proteins are reduced during the first few weeks of STZ-induced diabetes mellitus in rats 102 and correlate with increased vascular permeability. 103 Moreover, occludin levels drop in diabetic retinas, [103] [104] [105] and the localization of the protein at endothelial junctions is altered. 103 Our data are consistent with these findings, and we show that BMP9 prevents hyperglycemia-induced decrease of occludin expression and the delocalization of occludin at cell junctions. Along with changes in occludin localization, VE-cadherin levels were also decreased in hyperglycemic ECs. These changes may reflect increased internalization of VE-cadherin observed . E, Boyden chamber permeability assay on HUVECs transfected with occludin siRNA. Twenty-four hours post-siRNA transfection, cells were treated with D-glucose with or without BMP9 (10 ng/mL) for 18 h, followed by Evans blue permeability test (n=3 independent experiments). Data±SEM is shown. Differences between means were analyzed using a Student t test. NS indicates nonsignificant. *P<0.05, **P<0.01, ***P<0.001.
in hyperglycemia or may be a consequence of increased proteolytic degradation, which occurs as a result of increased MMP (matrix metalloproteinase) activity. 106 In hyperglycemic ECs, BMP9 contributed to the maintenance of VE-cadherin protein levels, which may be a consequence of its inhibition of Src and VE-cadherin phosphorylation, which have been associated with protein degradation. 107 Together, our data show that BMP9 prevents permeability induced by high glucose concentrations by maintaining the expression and junctional localization of occludin and VE-cadherin in ECs.
Although vascular complications have long been associated with diabetes mellitus, the complex series of events that lead to endothelial dysfunction in a hyperglycemic setting are less understood. Here, we show that reduced signaling by Alk1 in hyperglycemic conditions could contribute to increased vascular permeability. Several mechanisms could account for decreased Alk1 signaling in the presence of high glucose concentrations. It has been well documented that AGEs, which are formed in hyperglycemic conditions, can either activate inflammatory signaling, such as TNF-α (tumor necrosis factor-α), interleukin-6, and CRP (C-reactive protein), 108 or can interfere with the signaling of kinase receptors, including the EGFR (epidermal growth factor receptor). 109 Other mechanisms, including repressed transcriptional activity, or alterations in cellular localization have also been suggested to play a role in alterations of endothelial cell signaling in hyperglycemic conditions. In the case of Alk1, the transcription factor Sp1 has been shown to be a key regulator of ACVRL1 transcription. Chromatin immunoprecipitation assays demonstrated multiple Sp1-binding sites along the proximal promoter region of ACVRL1 in endothelial cells, and silencing of this factor results in decreased Alk1 expression. 110 Studies have demonstrated that Sp1 is subject to dynamic O-GlcNAcylation in hyperglycemic conditions and that this modification results in decreased transcriptional activity of the protein. 111 Given that the ACVRL1 promoter contains multiple Sp1-binding sites that are important for adequate gene expression, hyperglycemia may downregulate Alk1 expression at least, in part, by repressing Sp1 transcriptional activity.
In summary, we show here that hyperglycemia induces changes in endothelial cells leading to decreased Alk1 signaling, which in turn affect the junctional integrity of the endothelium and contribute to the pathological vascular leakage associated with DME. Taken together, these data suggest that Alk1 signaling plays important roles in maintaining vascular integrity and that BMP9 could help reverse heightened vascular permeability in DME.
